Compare TLYS & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLYS | COCH |
|---|---|---|
| Founded | 1982 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Clothing/Shoe/Accessory Stores | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3M | 49.7M |
| IPO Year | 2011 | N/A |
| Metric | TLYS | COCH |
|---|---|---|
| Price | $4.23 | $0.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 228.6K | 121.2K |
| Earning Date | 06-03-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.66 | $1.58 |
| Revenue Next Year | $1.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.36 |
| 52 Week High | $5.54 | $1.89 |
| Indicator | TLYS | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 58.09 |
| Support Level | $3.62 | $0.63 |
| Resistance Level | $4.59 | $0.88 |
| Average True Range (ATR) | 0.30 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 56.68 | 72.73 |
Tilly's Inc works as a specialty retailer of casual apparel, footwear, and accessories for young men, young women, boys, and girls. It offers an unparalleled selection of relevant brands, styles, colors, sizes, and price points. It delivers branded fashion, and core styles for tops, outerwear, bottoms, and dresses. It also provides backpacks, hats, sunglasses, headphones, handbags, watches, and jewelry. It markets its products under the brand names of Vans, RVCA, Adidas, Nike SB, and Hurley among others. It operates its stores in malls, lifestyle centers, power centers, community centers, outlet centers, street-front locations, and also through e-commerce.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.